Suppr超能文献

活化蛋白C对内毒素处理家兔组织型纤溶酶原激活剂诱导纤溶的增强作用

Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.

作者信息

Krishnamurti C, Young G D, Barr C F, Colleton C A, Alving B M

机构信息

Department of Hematology, Walter Reed Army Institute of Research, Washington, DC 20307-5100.

出版信息

J Lab Clin Med. 1991 Dec;118(6):523-30.

PMID:1744501
Abstract

Endotoxin-treated rabbits produce high levels of plasminogen activator inhibitor-1 (PAI-1), which inhibits fibrinolysis by neutralizing endogenous tissue-type plasminogen activator (t-PA). These animals will develop renal fibrin deposition when infused with ancrod, an enzyme that acts directly on fibrinogen. In normal rabbits with an intact fibrinolytic system, ancrod induces hypofibrinogenemia without fibrin deposition. Rabbit PAI-1 activity can be neutralized by recombinant human t-PA or by bovine activated protein C. The present study determined the efficacy of these two agents used alone or in combination in neutralizing increased PAI-1 activity and in preventing renal fibrin deposition in a rabbit model. Male New Zealand rabbits first received intravenous endotoxin to increase PAI-1 activity. Ancrod was infused intravenously during hour 4 to 5, and the kidneys were examined at hour 5.5. Renal fibrin deposition occurred in 100% (6 out of 6) of the endotoxin-treated rabbits that received ancrod; this was reduced to 14% (1 out of 7) for rabbits receiving t-PA (170 micrograms/kg) before and during the ancrod infusion. Fibrin deposition occurred in only 12% (1 out of 8) of the rabbits that received a 10-fold lower dose of t-PA (17 micrograms/kg) combined with activated protein C (1 mg/kg) before and during the ancrod. Activated protein C at this dose completely neutralized plasma PAI-1 activity. However, low-dose t-PA and activated protein C did not prevent fibrin deposition when used as single agents, with fibrin deposition occurring in 75% and 100% of rabbits, respectively. The data indicate that activated protein C can neutralize plasma PAI-1 activity in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

用内毒素处理的兔子会产生高水平的纤溶酶原激活物抑制剂-1(PAI-1),它通过中和内源性组织型纤溶酶原激活物(t-PA)来抑制纤维蛋白溶解。当给这些动物输注安克洛酶(一种直接作用于纤维蛋白原的酶)时,它们会出现肾纤维蛋白沉积。在纤维蛋白溶解系统完整的正常兔子中,安克洛酶会诱导低纤维蛋白原血症但不会出现纤维蛋白沉积。兔PAI-1活性可被重组人t-PA或牛活化蛋白C中和。本研究确定了这两种药物单独使用或联合使用在中和兔模型中升高的PAI-1活性以及预防肾纤维蛋白沉积方面的疗效。雄性新西兰兔首先接受静脉内毒素以增加PAI-1活性。在第4至5小时静脉输注安克洛酶,并在第5.5小时检查肾脏。接受安克洛酶的内毒素处理兔子中有100%(6/6)出现肾纤维蛋白沉积;在安克洛酶输注前和输注期间接受t-PA(170微克/千克)的兔子中,这一比例降至14%(1/7)。在安克洛酶输注前和输注期间接受低10倍剂量t-PA(17微克/千克)与活化蛋白C(1毫克/千克)联合治疗的兔子中,只有12%(1/8)出现纤维蛋白沉积。此剂量的活化蛋白C完全中和了血浆PAI-1活性。然而,低剂量t-PA和活化蛋白C单独使用时不能预防纤维蛋白沉积,分别有75%和100%的兔子出现纤维蛋白沉积。数据表明活化蛋白C可在体内中和血浆PAI-1活性。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验